Compare Agilent Technologies Inc (A) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Merck & Co., Inc. — how do they compare? Agilent Technologies Inc trades at $149 (market cap $42.00B), while Merck & Co., Inc. trades at $130.65 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 7.7× Agilent Technologies Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.
| A | MRK | |
|---|---|---|
Market Cap | $42.00B | $323.00B |
Sector | Health | Health |
52-Week High | $157.20 | $131.84 |
52-Week Low | $110.24 | $77.60 |
Enterprise Value | $43.55B | $369.77B |
Dividend Yield | 0.69% | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Merck (MRK) trades at $128.57, up 0.17% on the day, with a bullish technical outlook and strong institutional interest. Recent earnings beats and a $6.7 billion acquisition of Terns Pharmaceuticals bolster its oncology pipeline. The company maintains robust cash flow and a solid balance sheet, though a high P/E ratio of 104.74 reflects premium valuation expectations.
The stock offers upside to the $139.90 consensus price target, supported by analyst optimism and strategic M&A. Risks include integration challenges from acquisitions and patent expirations. Revenue growth and margin stability are key catalysts, but investors should monitor competitive pressures in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
